Use of Zebrafish Embryos for Small Molecule Screening Related to Cancer

Developmental Dynamics

Volumn 242, Issue 2, 2013, Pages 97-107

  Terriente, Javier ^a   Pujades, Cristina ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Zebrafish; cancer; drug screening; preclinical analysis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CHEMOTHERAPY; COST; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; NEOPLASMS; ZEBRAFISH;

DANIO RERIO;

EID: 84872745198     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.23912     Document Type: Review

References (112)

1. Akitake CM, Macurak M, Halpern ME, Goll MG. 2011. Transgenerational analysis of transcriptional silencing in zebrafish. Dev Biol 352:191-201.
2. Altmann KH. 2001. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 5:424-431.
3. Anchelin M, Murcia L, Alcaraz-Perez F, Garcia-Navarro EM, Cayuela ML. 2011. Behaviour of telomere and telomerase during aging and regeneration in zebrafish. PloS one 6:e16955.
4. Bakkers J. 2011. Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc Res 91:279-288.
5. Balciunas D, Ekker SC. 2005. Trapping fish genes with transposons. Zebrafish 1:335-341.
6. Balciunas D, Wangensteen KJ, Wilber A, Bell J, Geurts A, Sivasubbu S, Wang X, Hackett PB, Largaespada DA, McIvor RS, Ekker SC. 2006. Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet 2:e169.
7. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S. 2008. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 154:1400-1413.
8. Batlle E, Wilkinson DG. 2012. Molecular mechanisms of cell segregation and boundary formation in development and tumorigenesis. Cold Spring Harb Perspect Biol 4:a008227.
9. Camus S, Quevedo C, Menendez S, Paramonov I, Stouten PF, Janssen RA, Rueb S, He S, Snaar-Jagalska BE, Laricchia-Robbio L, Izpisua Belmonte JC. 2012. Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish. Oncogene 31:4333-4342.
10. Cao Y. 2008. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 100:113-131.
11. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307.
12. Ceccaldi A, Rajavelu A, Champion C, Rampon C, Jurkowska R, Jankevicius G, Senamaud-Beaufort C, Ponger L, Gagey N, Ali HD, Tost J, Vriz S, Ros S, Dauzonne D, Jeltsch A, Guianvarc'h D, Arimondo PB. 2011. C5-DNA methyltransferase inhibitors: from screening to effects on zebrafish embryo development. Chembiochem 12:1337-1345.
13. Chan J, Bayliss PE, Wood JM, Roberts TM. 2002. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 1:257-267.
14. Chan J, Mably JD. 2011. Dissection of cardiovascular development and disease pathways in zebrafish. Prog Mol Biol Transl Sci 100:111-153.
15. Chang TY, Pardo-Martin C, Allalou A, Wahlby C, Yanik MF. 2012. Fully automated cellular-resolution vertebrate screening platform with parallel animal processing. Lab Chip 12:711-716.
16. Cheng R, Ford BL, O'Neal PE, Mathews CZ, Bradford CS, Thongtan T, Barnes DW, Hendricks JD, Bailey GS. 1997. Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol Mar Biol Biotechnol 6:88-97.
17. Chico TJ, Ingham PW, Crossman DC. 2008. Modeling cardiovascular disease in the zebrafish. Trends Cardiovasc Med 18:150-155.
18. Choo BG, Kondrichin I, Parinov S, Emelyanov A, Go W, Toh WC, Korzh V. 2006. Zebrafish transgenic Enhancer TRAP line database (ZETRAP). BMC Dev Biol 6:5.
19. Crawford AD, Liekens S, Kamuhabwa AR, Maes J, Munck S, Busson R, Rozenski J, Esguerra CV, de Witte PA. 2011. Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants. PloS one 6:e14694.
20. Cross LM, Cook MA, Lin S, Chen JN, Rubinstein AL. 2003. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler Thromb Vasc Biol 23:911-912.
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
22. Day JJ, Sweatt JD. 2011. Epigenetic mechanisms in cognition. Neuron 70:813-829.
23. de Beco S, Ziosi M, Johnston LA. 2012. New frontiers in cell competition. Dev Dyn 241:831-841.
24. Distel M, Wullimann MF, Koster RW. 2009. Optimized Gal4 genetics for permanent gene expression mapping in zebrafish. Proc Natl Acad Sci U S A 106:13365.
25. Evensen L, Link W, Lorens JB. 2010. Imaged-based high-throughput screening for anti-angiogenic drug discovery. Curr Pharm Des 16:3958-3963.
26. Eyal-Giladi H. 1997. Establishment of the axis in chordates: facts and speculations. Development 124:2285-2296.
27. Feitsma H, Cuppen E. 2008. Zebrafish as a cancer model. Mol Cancer Res 6:685-694.
28. Finkel T, Serrano M, Blasco MA. 2007. The common biology of cancer and ageing. Nature 448:767-774.
29. Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. 2008. Zebrafish as a new animal model for movement disorders. J Neurochem 106:1991-1997.
30. Geissler K, Zach O. 2012. Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway. Ann Hematol 91:645-669.
31. Gerety SS, Wilkinson DG. 2011. Morpholino artifacts provide pitfalls and reveal a novel role for pro-apoptotic genes in hindbrain boundary development. Dev Biol 350:279-289.
32. Gerlai R. 2010. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. Molecules 15:2609-2622.
33. Gestri G, Link BA, Neuhauss SC. 2012. The visual system of zebrafish and its use to model human ocular diseases. Dev Neurobiol 72:302-327.
34. Giacomotto J, Segalat L. 2010. High-throughput screening and small animal models, where are we? Br J Pharmacol 160:204-216.
35. Goll MG, Anderson R, Stainier DY, Spradling AC, Halpern ME. 2009. Transcriptional silencing and reactivation in transgenic zebrafish. Genetics 182:747-755.
36. Hahn WC, Weinberg RA. 2002. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
37. Halpern ME, Rhee J, Goll MG, Akitake CM, Parsons M, Leach SD. 2008. Gal4/UAS transgenic tools and their application to zebrafish. Zebrafish 5:97-110.
38. Hamm EE, Ballard JD. 2007. Elucidating the in vivo targets of bacterial toxins. Future Microbiol 2:85-92.
39. Hampson RJ, Wyatt MD. 2011. Whole organism based techniques and approaches in early stage oncology drug discovery-patents and trends. Recent Pat Endocr Metab Immune Drug Discov 5:183-191.
40. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
41. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
42. Jackson-Grusby L. 2002. Modeling cancer in mice. Oncogene 21:5504-5514.
43. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer JClin 61:69-90.
44. Jesuthasan S. 1998. Furrow-associated microtubule arrays are required for the cohesion of zebrafish blastomeres following cytokinesis. J Cell Sci 111(Pt 24):3695-3703.
45. Jesuthasan S, Stahle U. 1997. Dynamic microtubules and specification of the zebrafish embryonic axis. Curr Biology 7:31-42.
46. Kawakami K, Abe G, Asada T, Asakawa K, Fukuda R, Ito A, Lal P, Mouri N, Muto A, Suster ML, Takakubo H, Urasaki A, Wada H, Yoshida M. 2010. zTrap: zebrafish gene trap and enhancer trap database. BMC Dev Biol 10:105.
47. Kawakami K, Takeda H, Kawakami N, Kobayashi M, Matsuda N, Mishina M. 2004. A transposon-mediated gene trap approach identifies developmentally regulated genes in zebrafish. Dev Cell 7:133-144.
48. Kiefer JC. 2007. Epigenetics in development. Dev Dyn 236:1144-1156.
49. Lam K, Zhang DE. 2012. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci 17:1120-1139.
50. Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, Lin S, Prochownik E, Trede NS, Zon LI, Look AT. 2003. Myc-induced T cell leukemia in transgenic zebrafish. Science 299:887-890.
51. Langheinrich U, Hennen E, Stott G, Vacun G. 2002. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 12:2023-2028.
52. Laux DW, Febbo JA, Roman BL. 2011. Dynamic analysis of BMP-responsive smad activity in live zebrafish embryos. Dev Dyn 240:682-694.
53. Lawson ND, Weinstein BM. 2002. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248:307-318.
54. Lieschke GJ, Currie PD. 2007. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 8:353-367.
55. Liu S, Leach SD. 2011. Zebrafish models for cancer. Annu Rev Pathol 6:71-93.
56. Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S. 1997. GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development 124:4105-4111.
57. Maes J, Verlooy L, Buenafe OE, de Witte PA, Esguerra CV, Crawford AD. 2012. Evaluation of 14 organic solvents and carriers for screening applications in zebrafish embryos and larvae. PloS one 7:e43850.
58. Mahadevan LC, Willis AC, Barratt MJ. 1991. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 65:775-783.
59. Martin CC, Laforest L, Akimenko MA, Ekker M. 1999. A role for DNA methylation in gastrulation and somite patterning. Dev Biol 206:189-205.
60. Martinez-Arias A. 2001. Epithelial mesenchymal interactions in cancer and development. Cell 105:425-431.
61. Massague J. 2008. TGFbeta in cancer. Cell 134:215-230.
62. Meijer AH, Spaink HP. 2011. Host-pathogen interactions made transparent with the zebrafish model. Curr Drug Targets 12:1000-1017.
63. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, Tsang M. 2009. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 5:680-687.
64. Molina GA, Watkins SC, Tsang M. 2007. Generation of FGF reporter transgenic zebrafish and their utility in chemical screens. BMC Dev Biol 7:62.
65. Moon HS, Jacobson EM, Khersonsky SM, Luzung MR, Walsh DP, Xiong W, Lee JW, Parikh PB, Lam JC, Kang TW, Rosania GR, Schier AF, Chang YT. 2002. A novel microtubule destabilizing entity from orthogonal synthesis of triazine library and zebrafish embryo screening. J Am Chem Soc 124:11608-11609.
66. Moro E, Ozhan-Kizil G, Mongera A, Beis D, Wierzbicki C, Young RM, Bournele D, Domenichini A, Valdivia LE, Lum L, Chen C, Amatruda JF, Tiso N, Weidinger G, Argenton F. 2012. In vivo Wnt signaling tracing through a transgenic biosensor fish reveals novel activity domains. Dev Biol 366:327-340.
67. Murphey RD, Stern HM, Straub CT, Zon LI. 2006. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem Biol Drug Des 68:213-219.
68. Pardo-Martin C, Chang TY, Koo BK, Gilleland CL, Wasserman SC, Yanik MF. 2010. High-throughput in vivo vertebrate screening. Nat Methods 7:634-636.
69. Parng C. 2005. In vivo zebrafish assays for toxicity testing. Curr Opin Drug Discov Dev 8:100-106.
70. Parsons MJ, Pisharath H, Yusuff S, Moore JC, Siekmann AF, Lawson N, Leach SD. 2009. Notch-responsive cells initiate the secondary transition in larval zebrafish pancreas. Mech Dev 126:898-912.
71. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI. 2005. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15:249-254.
72. Perz-Edwards A, Hardison NL, Linney E. 2001. Retinoic acid-mediated gene expression in transgenic reporter zebrafish. Dev Biol 229:89-101.
73. Peterson RT, Link BA, Dowling JE, Schreiber SL. 2000. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci U S A 97:12965-12969.
74. Peterson RT, MacRae CA. 2012. Systematic approaches to toxicology in the zebrafish. Annu Rev Pharmacol Toxicol 52:433-453.
75. Portela A, Esteller M. 2010. Epigenetic modifications and human disease. Nat Biotechnol 28:1057-1068.
76. Pyati UJ, Look AT, Hammerschmidt M. 2007. Zebrafish as a powerful vertebrate model system for in vivo studies of cell death. Semin Cancer Biol 17:154-165.
77. Radi M, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, Musumeci F, Schenone S, Lorens JB, Botta M. 2012. A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation. Bioorg Med Chem Lett 22:5579-5583.
78. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. 2004. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 30:237-247.
79. Rocke J, Lees J, Packham I, Chico T. 2009. The zebrafish as a novel tool for cardiovascular drug discovery. Recent Pat Cardiovasc Drug Discov 4:1-5.
80. Rovira M, Huang W, Yusuff S, Shim JS, Ferrante AA, Liu JO, Parsons MJ. 2011. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc Natl Acad Sci U S A 108:19264-19269.
81. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. 1996. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15:827-838.
82. Rubinstein AL. 2006. Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2:231-240.
83. Rubinstein AL, Lee D, Luo R, Henion PD, Halpern ME. 2000. Genes dependent on zebrafish cyclops function identified by AFLP differential gene expression screen. Genesis 26:86-97.
84. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, Imamura T, Ogawa M, Masai H, Miyawaki A. 2008. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132:487-498.
85. Saydmohammed M, Vollmer LL, Onuoha EO, Vogt A, Tsang M. 2011. A high-content screening assay in transgenic zebrafish identifies two novel activators of fgf signaling. Birth Defects Res C Embryo Today 93:281-287.
86. Schwend T, Loucks EJ, Ahlgren SC. 2010. Visualization of Gli activity in craniofacial tissues of hedgehog-pathway reporter transgenic zebrafish. PloS one 5:e14396.
87. Sipes NS, Padilla S, Knudsen TB. 2011. Zebrafish: as an integrative model for twenty-first century toxicity testing. Birth Defects Res C Embryo Today 93:256-267.
88. Stern HM, Zon LI. 2003. Cancer genetics and drug discovery in the zebrafish. Nature reviews. Cancer 3:533-539.
89. Stoletov K, Klemke R. 2008. Catch of the day: zebrafish as a human cancer model. Oncogene 27:4509-4520.
90. Sugiyama M, Sakaue-Sawano A, Iimura T, Fukami K, Kitaguchi T, Kawakami K, Okamoto H, Higashijima SI, Miyawaki A. 2009. Illuminating cell-cycle progression in the developing zebrafish embryo. Proc Natl Acad Sci U S A 106:20812-20817.
91. Tishler RB, Calderwood SK, Coleman CN, Price BD. 1993. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53:2212-2216.
92. Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, Baranowski TC, Rubinstein AL, Doan TN, Dingledine R, Sandberg EM. 2007. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 67:11386-11392.
93. Trinh le A, Hochgreb T, Graham M, Wu D, Ruf-Zamojski F, Jayasena CS, Saxena A, Hawk R, Gonzalez-Serricchio A, Dixson A, Chow E, Gonzales C, Leung HY, Solomon I, Bronner-Fraser M, Megason SG, Fraser SE. 2011. A versatile gene trap to visualize and interrogate the function of the vertebrate proteome. Genes Dev 25:2306-2320.
94. Tsang M. 2010. Zebrafish: a tool for chemical screens. Birth Defects Res C Embryo Today 90:185-192.
95. Tuffery P, Derreumaux P. 2012. Flexibility and binding affinity in protein-ligand, protein-protein and multi-component protein interactions: limitations of current computational approaches. J R Soc Interface 9:20-33.
96. van Ham TJ, Mapes J, Kokel D, Peterson RT. 2010. Live imaging of apoptotic cells in zebrafish. FASEB J 24:4336-4342.
97. Vogt A, Cholewinski A, Shen X, Nelson SG, Lazo JS, Tsang M, Hukriede NA. 2009a. Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn 238:656-663.
98. Vogt A, Codore H, Day BW, Hukriede NA, Tsang M. 2010. Development of automated imaging and analysis for zebrafish chemical screens. J Vis Exp 1900.
99. Vogt A, McPherson PA, Shen X, Balachandran R, Zhu G, Raccor BS, Nelson SG, Tsang M, Day BW. 2009b. High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic (-)-pironetin and analogs. Chem Biol Drug Des 74:358-368.
100. Walker SL, Ariga J, Mathias JR, Coothankandaswamy V, Xie X, Distel M, Koster RW, Parsons MJ, Bhalla KN, Saxena MT, Mumm JS. 2012. Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish. PloS one 7:e29916.
101. Weinstein BM, Stemple DL, Driever W, Fishman MC. 1995. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med 1:1143-1147.
102. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, Chen F, Long HK, Kramer M, Datta S, Neuberg D, Granter S, Young RA, Morrison S, Wheeler GN, Zon LI. 2011. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471:518-522.
103. Wodarz A, Nathke I. 2007. Cell polarity in development and cancer. Nat Cell Biol 9:1016-1024.
104. Woods IG, Kelly PD, Chu F, Ngo-Hazelett P, Yan YL, Huang H, Postlethwait JH, Talbot WS. 2000. A comparative map of the zebrafish genome. Genome Res 10:1903-1914.
105. Yamasaki H, Era T, Asou N, Sanada I, Matutes E, Yamaguchi K, Takatsuki K. 1995. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia 9:1147-1153.
106. Yang J, Weinberg RA. 2008. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818-829.
107. Yanik MF, Rohde CB, Pardo-Martin C. 2011. Technologies for micromanipulating, imaging, and phenotyping small invertebrates and vertebrates. Annu Rev Biomed Eng 13:185-217.
108. Yeh JR, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT. 2008. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 135:401-410.
109. Yeh JR, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. 2009.Discovering chemical modifiers ofoncogene-regulated hematopoietic differentiation. Nat Chem Biol 5:236-243.
110. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.
111. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: past, present and future. Nature reviews. Drug Discov 5:37-50.
112. Zhu Z, Cuozzo J. 2009. Review article: high-throughput affinity-based technologies for small-molecule drug discovery. J Biomol Screen 14:1157-1164.